Microfluidic Chip, also known as lab-on-a-chip or biochip, is the use of MEMS technology to microscale a large laboratory system on a glass or plastic substrate, in order to replicate the complex biological and chemical reaction process, complete the experiment quickly and automatically. It is characterized by the miniaturized construction of fluid channels, reaction chambers and other functional components at the micron scale. This technology will bring a subversive breakthrough to the diagnostic fields of genes, immunity, microbiology and clinical chemistry, leading to possibility of early diagnosis, early prevention of many diseases threatening human health, such as cancer, cardiovascular and cerebrovascular diseases. The combination of biochip and biological targeted drugs pushes clinical medicine towards personalized precision medical diagnosis and treatment.

Holosensor Medical Technology Ltd (Holosensor) follows the pulse of international cutting-edge technology's innovation as well as the market demand of the pharmaceutical industry. Based on our core microfluidic technology, we constantly develop medical devices and reagents for liquid biopsy and nucleic acid detection of pathogens. Our products are launched in many diagnostic fields such as circulating tumor cells(CTC), nucleic acid detection of infectious pathogens and novel coronavirus(SARS-Cov-2).  Holosensor has established a close partnership with the Cambridge University and other international scientific research institutions to provide faster and efficient diagnostic results for clinical use.